Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands

Vaccine

Volumn 25, Issue 33, 2007, Pages 6245-6256

  Boot, Hein J ^a   Wallenburg, Iris ^b   de Melker, Hester E ^a   Mangen, Marie José M ^a   Gerritsen, Annette A M ^a   van der Maas, Nicoline A ^a   Berkhof, Johannes ^c   Meijer, Chris J L M ^c   Kimman, Tjeerd G ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b Rathenau Institute KNAW   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer; Cost effectiveness ratio; HPV vaccination; National Immunization Program; The Netherlands

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; AUTOIMMUNE DISEASE; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG COST; DRUG ERUPTION; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HERD IMMUNITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LONG TERM CARE; NETHERLANDS; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; UTERINE CERVIX CARCINOMA; VACCINATION; VIRUS INFECTION; VIRUS TRANSMISSION;

AGE DISTRIBUTION; CHILD; COITUS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; INCIDENCE; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY OF LIFE; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 34547118830     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.061     Document Type: Article

References (108)

1. Abbink F, Oomen PJ, Zwakhals SLN, Melker HE, Ambler-Huiskes A. Immunisation coverage in The Netherlnds as of 1 January 2005. National Institute of Health and the Environment 2006; Report 210021005.
2. Arany I., and Tyring S.K. Systemic immunosuppression by HIV infection influences HPV transcription and thus local immune responses in condyloma acuminatum. Int J STD AIDS 9 5 (1998 May) 268-271
3. Arias-Pulido H., Peyton C.L., Torrez-Martinez N., Anderson D.N., and Wheeler C.M. Human papillomavirus type 18 variant lineages in United States populations characterized by sequence analysis of LCR-E6, E2, and L1 regions. Virology 338 1 (2005) 22-34
4. Bais A.G., van Kemenade F.J., Berkhof J., Verheijen R.H., Snijders P.J., Voorhorst F., et al. Human papillomavirus testing on self-sampled cervicovaginal brushes: an effective alternative to protect nonresponders in cervical screening programs. Int J Cancer 120 7 (2007) 1505-1510
5. Barnabas R.V., Laukkanen P., Koskela P., Kontula O., Lehtinen M., and Garnett G.P. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 3 5 (2006) e138
6. Baseman J.G., and Koutsky L.A. The epidemiology of human papillomavirus infections. J Clin Virol 32 Suppl 1 (2005) S16-S24
7. Bekkers R.L., Meijer C.J., Massuger L.F., Snijders P.J., and Melchers W.J. Effects of HPV detection in population-based screening programmes for cervical cancer; a Dutch moment. Gynecol Oncol 100 3 (2006) 451-454
8. Berkhof J., de Bruijne M.C., Zielinski G.D., Bulkmans N.W., Rozendaal L., Snijders P.J., et al. Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis. Int J Cancer 118 7 (2006) 1759-1768
9. Berkhof J., de Bruijne M.C., Zielinski G.D., and Meijer C.J. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in The Netherlands. Int J Cancer 115 2 (2005) 268-275
10. Boot H.J., de Melker H.E., Stolk E.A., de Wit G.A., and Kimman T.G. Assessing the introduction of universal varicella vaccination in The Netherlands. Vaccine 24 37-39 (2006) 6288-6299
11. Bos A.B., Rebolj M., Habbema J.D., and van Ballegooijen M. Nonattendance is still the main limitation for the effectiveness of screening for cervical cancer in The Netherlands. Int J Cancer 119 10 (2006) 2372-2375
12. Bos A.B., van Ballegooijen M., van den Akker-van Marle M.E., and Habbema J.D. Less pap-2 results ('minor abnormalities') in the population screening for cervical cancer since the introduction of new guidelines in 1996. Ned Tijdschr Geneeskd 146 34 (2002) 1586-1590
13. Bosch F.X., Lorincz A., Munoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 4 (2002) 244-265
14. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 6 (1995) 3959-3963
15. Brink A.A., Snijders P.J., Meijer C.J., Berkhof J., and Verheijen R.H. HPV testing in cervical screening. Best Pract Res Clin Obstet Gynaecol 20 2 (2006) 253-266
16. Brouwer WBF, Rutten FFH. De hoogte van disconteervoeten in economische evaluaties: is de tijd rijp voor een nieuwe richtlijn?
17. Brown D.R., Schroeder J.M., Bryan J.T., Stoler M.H., and Fife K.H. Detection of multiple human papillomavirus types in Condylomata acuminata lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 37 10 (1999 Oct) 3316-3322
18. Bulk S., Berkhof J., Bulkmans N.W., Zielinski G.D., Rozendaal L., van Kemenade F.J., et al. Preferential risk of HPV16 for squamous cell carcinoma and of HPV18 for adenocarcinoma of the cervix compared to women with normal cytology in The Netherlands. Br J Cancer 94 1 (2006 Jan) 171-175
19. Bulk S., Van Kemenade F.J., Rozendaal L., and Meijer C.J. The Dutch CISOE-A framework for cytology reporting increases efficacy of screening upon standardisation since 1996. J Clin Pathol 57 4 (2004) 388-393
20. Bulk S., Visser O., Rozendaal L., Verheijen R.H., and Meijer C.J. Cervical cancer in The Netherlands 1989-1998: decrease of squamous cell carcinoma in older women, increase of adenocarcinoma in younger women. Int J Cancer 113 6 (2005) 1005-1009
21. Bulkmans N.W., Bleeker M.C., Berkhof J., Voorhorst F.J., Snijders P.J., and Meijer C.J. Prevalence of types 16 and 33 is increased in high-risk human papillomavirus positive women with cervical intraepithelial neoplasia grade 2 or worse. Int J Cancer 117 2 (2005) 177-181
22. Bulkmans N.W., Rozendaal L., Snijders P.J., Voorhorst F.J., Boeke A.J., Zandwijken G.R., et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 110 1 (2004) 94-101
23. Burchell A.N., Richardson H., Mahmud S.M., Trottier H., Tellier P.P., Hanley J., et al. Modeling the sexual transmissibility of human papillomavirus infection using stochastic computer simulation and empirical data from a cohort study of young women in Montreal, Canada. Am J Epidemiol 163 6 (2006 Mar) 534-543
24. Burchell A.N., Winer R.L., de Sanjose S., and Franco E.L. Epidemiology and transmission dynamics of genital HPV infection. Vaccine 24 Suppl 3 (2006) S52-S61 [chapter 6]
25. Cason J., Kaye J.N., Jewers R.J., Kambo P.K., Bible J.M., Kell B., et al. Perinatal infection and persistence of human papillomavirus types 16 and 18 in infants. J Med Virol 47 3 (1995) 209-218
26. CBG - RIVM - GR. HPV-vaccins: tussen registratie en implementatie. Info-Map.
27. Clifford G., Franceschi S., Diaz M., Munoz N., and Villa L.L. HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24 Suppl 3 (2006) S26-S34 [chapter 3]
28. Clifford G.M., Gallus S., Herrero R., Munoz N., Snijders P.J., Vaccarella S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 9490 (2005) 991-998
29. Clifford G.M., Rana R.K., Franceschi S., Smith J.S., Gough G., and Pimenta J.M. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 14 5 (2005) 1157-1164
30. Clifford G.M., Smith J.S., Plummer M., Munoz N., and Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88 1 (2003) 63-73
31. De Graaf H, Meijer S, Poelman J, Vanwesenbeeck I. Seks onder je 25e: seksuele gezondheid van jongeren in Nederland anno 2005. Rapport Rutgers Nisso Groep.
32. De Villiers E.M. Heterogeneity of the human papillomavirus group. J Virol 63 11 (1989) 4898-4903
33. De Villiers E.M. Taxonomic classification of papillomaviruses. Papillomavirus Rep 12 (2001) 57-63
34. De Wit G.A., and Schuit J. Overwegingen rondom de implementatie van kosten-effectieve public health interventies. Tijdschrift Voor Gezondheidswetenschappen 84 5 (2006) 11-13
35. Dillner J., Lenner P., Lehtinen M., Eklund C., Heino P., Wiklund F., et al. A population-based seroepidemiological study of cervical cancer. Cancer Res 54 1 (1994) 134-141
36. Dutch Cancer Registry; 2006.
37. Elbasha E.H., and Galvani A.P. Vaccination against multiple HPV types. Math Biosci 197 1 (2005) 88-117
38. EMEA. European Public Assessment Report Gardasil 2006 Oct.
39. Franceschi S., Herrero R., Clifford G.M., Snijders P.J., Arslan A., Anh P.T., et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006)
40. Franco E.L., Cuzick J., Hildesheim A., and de Sanjose S. Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24 Suppl 3 (2006) S171-S177 [chapter 20]
41. Garnett G.P., Kim J.J., French K., and Goldie S.J. Modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine 24 Suppl 3 (2006) S178-S186 [chapter 21]
42. Gezondheidsraad. Jaarbericht bevolkingsonderzoek; 2006.
43. Ghim S., Newsome J., Bell J., Sundberg J.P., Schlegel R., and Jenson A.B. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Exp Mol Pathol 68 3 (2000) 147-151
44. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 33/34 (2006) 5937-5949
45. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 8 (2004) 604-615
46. Greer C.E., Wheeler C.M., Ladner M.B., Beutner K., Coyne M.Y., Liang H., et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 33 8 (1995) 2058-2063
47. Hagensee M.E., Cameron J.E., Leigh J.E., and Clark R.A. Human papillomavirus infection and disease in HIV-infected individuals. Am J Med Sci 328 1 (2004) 57-63
48. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
49. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
50. Henquet C.J., Jansen M.W., Buwalda P.J., and Neumann H.A. Sexually transmitted diseases in Limburg in 1997; prevalence according to a survey of family practitioners and specialists and according to reports from microbiological laboratories. Ned Tijdschr Geneeskd 144 13 (2000) 608-612
51. Hermonat P.L., You H., Chiriva-Internati C.M., and Liu Y. Analysis of adeno-associated virus and HPV interaction. Methods Mol Med 119 (2005) 397-409
52. Hildesheim A., Mann V., Brinton L.A., Szklo M., Reeves W.C., and Rawls W.E. Herpes simplex virus type 2: a possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer. Int J Cancer 49 3 (1991) 335-340
53. Jansen K.U., and Shaw A.R. Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 55 (2004) 319-331
54. Kahn J.A. Vaccination as a prevention strategy for human papillomavirus-related diseases. J Adolesc Health 37 6 Suppl (2005) S10-S16
55. Kaye J.N., Cason J., Pakarian F.B., Jewers R.J., Kell B., Bible J., et al. Viral load as a determinant for transmission of human papillomavirus type 16 from mother to child. J Med Virol 44 4 (1994) 415-421
56. Kimman T.G., Boot H.J., Berbers G.A., Vermeer-de Bondt P.E., Ardine de Wit G., and de Melker H.E. Developing a vaccination evaluation model to support evidence-based decision making on national immunization programs. Vaccine 24 22 (2006) 4769-4778
57. Kirnbauer R., Hubbert N.L., Wheeler C.M., Becker T.M., Lowy D.R., and Schiller J.T. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 86 7 (1994) 494-499
58. Kitchener H.C., Almonte M., Wheeler P., Desai M., Gilham C., Bailey A., et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br J Cancer 95 1 (2006) 56-61
59. Kitchener H.C., Castle P.E., and Cox J.T. Achievements and limitations of cervical cytology screening. Vaccine 24 Suppl 3 (2006) S63-S70 [chapter 7]
60. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (2002) 1645-1651
61. Koutsky L.A., and Harper D.M. Current findings from prophylactic HPV vaccine trials. Vaccine 24 Suppl 3 (2006) S114-S121 [chapter 13]
62. Krul E.J., Van De Vijver M.J., Schuuring E., Van Kanten R.W., Peters A.A., and Fleuren G.J. Human papillomavirus in malignant cervical lesions in Surinam, a high-risk country, compared to The Netherlands, a low-risk country. Int J Gynecol Cancer 9 3 (1999) 206-211
63. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 6 (2003) 781-789
64. Lacey C.J., Lowndes C.M., and Shah K.V. Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24 Suppl 3 (2006) S35-S41 [chapter 4]
65. Liaw K.L., Hildesheim A., Burk R.D., Gravitt P., Wacholder S., Manos M.M., et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 183 1 (2001) 8-15
66. Lowndes C.M. Vaccines for cervical cancer. Epidemiol Infect 134 1 (2006) 1-12
67. Magnusson P.K., Lichtenstein P., and Gyllensten U.B. Heritability of cervical tumours. Int J Cancer 88 5 (2000) 698-701
68. Maissi E., Marteau T.M., Hankins M., Moss S., Legood R., and Gray A. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. BMJ 328 7451 (2004) 1293
69. Manhart L.E., and Koutsky L.A. Do condoms prevent genital HPV infection, external genital warts, or cervical neoplasia? A meta-analysis. Sex Transm Dis 29 11 (2002) 725-735
70. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 1 (2006) 18-27
71. Mays R.M., Sturm L.A., and Zimet G.D. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med 58 7 (2004) 1405-1413
72. Moscicki A.B. Impact of HPV infection in adolescent populations. J Adolesc Health 37 6 Suppl (2005) S3-S9
73. O'Mahony C. Genital warts: current and future management options. Am J Clin Dermatol 6 4 (2005) 239-243
74. Olsen A.O., Orstavik I., Dillner J., Vestergaard B.F., and Magnus P. Herpes simplex virus and human papillomavirus in a population-based case-control study of cervical intraepithelial neoplasia grade II-III. APMIS 106 3 (1998) 417-424
75. Olshen E., Woods E.R., Austin S.B., Luskin M., and Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health 37 3 (2005) 248-251
76. Palefsky J.M., Gillison M.L., and Strickler H.D. HPV vaccines in immunocompromised women and men. Vaccine 24 Suppl 3 (2006) S140-S146 [chapter 16]
77. Parkin D.M., and Bray F. The burden of HPV-related cancers. Vaccine 24 Suppl 3 (2006) S11-S25 [chapter 2]
78. Rousseau M.C., Pereira J.S., Prado J.C., Villa L.L., Rohan T.E., and Franco E.L. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 184 12 (2001) 1508-1517
79. Sanders G.D., and Taira A.V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 9 1 (2003) 37-48
80. Sattler C. Efficacy of a prophylactic quadrivalent human papillomavirus (HPV) types 6,11,16,18 L1 virus-like particle vaccine for prevention of cervical dysplasia and external genetial lesions (EGL). Abstract of ICAAC (2005)
81. Sherris J., Friedman A., Wittet S., Davies P., Steben M., and Saraiya M. Education, training, and communication for HPV vaccines. Vaccine 24 Suppl 3 (2006) S210-S218 [chapter 25]
82. Siddiqui M.A., and Perry C.M. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 66 9 (2006) 1263-1271 discussion 1272-1273
83. Silins I., Wang Z., Avall-Lundqvist E., Frankendal B., Vikmanis U., Sapp M., et al. Serological evidence for protection by human papillomavirus (HPV) type 6 infection against HPV type 16 cervical carcinogenesis. J Gen Virol 80 Pt 11 (1999) 2931-2936
84. Smith JF, Brownlow MK, Brown MJ, Esser MT, Ruiz W, Brown DR. Gardasil antibodies cross-neutralize pseudovirion infection of vaccine-related HPV types. 23rd International Papillomavirus Conference and Clinical Workshop in Prague 2006 Sep; Abstract PL 1-6.
85. Steiner M.J., and Cates Jr. W. Condoms and sexually-transmitted infections. N Engl J Med 354 25 (2006) 2642-2643
86. Stratton K.R., Durch J.S., and Lawrence R.S. Vaccines for the 21st century: a tool for decisionmaking. Human papillomavirus (Appendix 11) (2000), National academy press, Whasington
87. Taira A.V., Neukermans C.P., and Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 10 11 (2004) 1915-1923
88. Tay S.K. Genital oncogenic human papillomavirus infection: a short review on the mode of transmission. Ann Acad Med Singapore 24 4 (1995) 598-601
89. Torrisi A., Del Mistro A., Onnis G.L., Merlin F., Bertorelle R., and Minucci D. Colposcopy, cytology and HPV-DNA testing in HIV-positive and HIV-negative women. Eur J Gynaecol Oncol 21 2 (2000) 168-172
90. U.S. Food and Drugs Administration. Product approval information concerning Gardasil. 2007; http://www.fda.gov/cber/products/hpvmer040307.htm.
91. Van Baal P.H., Hoeymans N., Hoogenveen R.T., de Wit G.A., and Westert G.P. Disability weights for comorbidity and their influence on health-adjusted life expectancy. Popul Health Metr 4 (2006) 1
92. Van Ballegooijen M. Effects and costs of cervical cancer screening. Disseration at the Erasmus Universtity Rotterdam 1998; chapter 6.
93. Van Oortmarssen G.J., and Habbema J.D. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 64 3 (1991) 559-565
94. Vandepapeliere P., Barrasso R., Meijer C.J., Walboomers J.M., Wettendorff M., Stanberry L.R., et al. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis 192 12 (2005) 2099-2107
95. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24 27/28 (2006) 5571-5583
96. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
97. ® HPV quadrivalent vaccine, 2006.
98. White W.I., Wilson S.D., Palmer-Hill F.J., Woods R.M., Ghim S.J., Hewitt L.A., et al. Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 73 6 (1999) 4882-4889
99. WHO. Investing in Health for Economic Development. Geneva, Switserland, 2001.
100. Winer R.L., Hughes J.P., Feng Q., O'Reilly S., Kiviat N.B., Holmes K.K., et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 354 25 (2006) 2645-2654
101. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., and Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 3 (2003) 218-226
102. Woodman C.B., Collins S., Winter H., Bailey A., Ellis J., Prior P., et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 357 9271 (2001) 1831-1836
103. Wright T.C., Bosch F.X., Franco E.L., Cuzick J., Schiller J.T., Garnett G.P., et al. HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine 24 Suppl 3 (2006) S251-S261 [chapter 30]
104. Wright T.C., Van Damme P., Schmitt H.J., and Meheus A. HPV vaccine introduction in industrialized countries. Vaccine 24 Suppl 3 (2006) S122-S131 [chapter 14]
105. Xi L.F., Koutsky L.A., Galloway D.A., Kuypers J., Hughes J.P., Wheeler C.M., et al. Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst 89 11 (1997) 796-802
106. Yamada T., Manos M.M., Peto J., Greer C.E., Munoz N., Bosch F.X., et al. Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. J Virol 71 3 (1997) 2463-2472
107. Zimet G.D., Liddon N., Rosenthal S.L., Lazcano-Ponce E., and Allen B. Psychosocial aspects of vaccine acceptability. Vaccine 24 Suppl 3 (2006) S201-S209 [chapter 24]
108. Zimet G.D., Perkins S.M., Sturm L.A., Bair R.M., Juliar B.E., and Mays R.M. Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health 37 3 (2005) 179-186